A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients

• Published in: Psychopharmacology Vol. 114; no. 1; p. 24
• Main Authors: Dencker, S J, Giös, I, Mårtensson, E, Nordén, T, Nyberg, G, Persson, R, Roman, G, Stockman, O, Svärd, K O
• Format: Journal Article
• Language: English
• Published: Germany 01.02.1994
• Subjects: Adult; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Female; Haloperidol - administration & dosage; Haloperidol - analogs & derivatives; Haloperidol - pharmacokinetics; Haloperidol - therapeutic use; Humans; Male; Middle Aged; Perphenazine - administration & dosage; Perphenazine - analogs & derivatives; Perphenazine - pharmacokinetics; Perphenazine - therapeutic use; Prolactin - blood; Schizophrenia - drug therapy; Schizophrenia - metabolism; Schizophrenic Psychology; Spectrophotometry, Ultraviolet
• ISSN: 0033-3158
• DOI: 10.1007/BF02245440

The purpose of the study was to investigate clinical and pharmacokinetic parameters concerning perphenazine decanoate (PD) and haloperidol decanoate (HD) with an interval of 3 weeks during a study period of 51 weeks. This was done by using the available drug preparations in chronic schizophrenic patients in a randomised, double-blind, cross-over, multicentre study. In addition, an elimination phase of 6 weeks was added, when no IM injections of the depot drugs were given. Twenty-nine patients in a stable neuroleptic maintenance phase entered the study. The patients were rated during the trial according to the CPRS-SCHZ and CGI scales, the UKU side effect scale and serum concentrations of the drugs and prolactin were monitored. There was no significant difference between the drugs in antipsychotic efficacy or side effects. Thus, the doses were equipotent with regard to the CPRS-SCHZ scores. However, the patients' global improvement rating was higher for PD (52%) than for HD (39%) (P > 0.05). The elimination of both drugs was very slow. No interaction effects between PD and HD were observed. The serum levels of HD were in most patients lower than those recommended for acute-subacute treatment. The mean doses were 117 mg (0.29 mmol), range 20-313 mg PD and 120 mg (0.32 mmol), range 20-350 mg HD. The serum concentrations in nmol/L of perphenazine and haloperidol (week 24) were 0.8-15.9 and 2.3-46.7, respectively.